23 stories mentioning ASNDUpdated 3d ago
Every FINWIRES story that references ASND, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Mads Bodenhoff, Senior Vice President and Principal Accounting Officer, on September 08, 2026, sold 3,000 shares in Ascendis Pharma (ASND) for $810,570.SEC Filing:https://www.sec.gov/Archives/edgar/data/1612042/000161071726000409/xslF345X05/form4.xml
European equities traded in the US as American depositary receipts opened the week slightly lower late Monday morning, declining 0.12% to 1,952.52 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by pharmaceutical company Ascendis Pharma (ASND) and 3D printer company Materialise (MTLS), which rose 6.6% and 2.8%, respectively. They were followed by petroleum refiner Equinor (EQNR) and oil and gas company Eni (E), which were up 2.7% and 2.6%, respectively.The decliners from continental Europe were led by internet browser company Opera (OPRA) and biotech firm Evaxion (EVAX), which fell 1.9% and 1.7% respectively. They were followed by telecommunications company Nokia (NOK) and accommodations booking site trivago (TRVG), which were down 1.3% and 1.2% respectively.The gainers from the UK were led by biopharmaceutical company Mereo BioPharma Group (MREO) and software firm Endava (DAVA), which advanced 14% and 1.9% respectively. They were followed by oil and gas companies BP (BP) and Shell (SHEL), which increased 1.3% and 0.9% respectively.The decliners from the UK and Ireland were led by biopharmaceutical companies NuCana (NCNA) and Biodexa Pharmaceuticals (BDRX), which dropped 16% and 5.9% respectively. They were followed by biopharmaceutical company Akari Therapeutics (AKTX) and pharmaceutical company Silence Therapeutics (SLN), which increased 3.7% and 2.3% respectively.
Ascendis Pharma A/S (ASND) has an average rating of buy and mean price target of $310.61, according to analysts polled by FactSet.
Ascendis Pharma A/S (ASND) has an average rating of buy and mean price target of $310.61, according to analysts polled by FactSet.
Ascendis Pharma's (ASND) Q2 results showed a solid rebound for Yorvipath, while the early launch of Yuviwel in achondroplasia is progressing well, RBC Capital Markets said in a Thursday note.According to the note, Yorvipath revenue rose to 252 million euros ($291.8 million) from 197 million euros in Q1, slightly above RBC's estimate of 249 million euros. The sequential increase indicated steady uptake as management reiterated about 1,000 unique US patient starts per quarter at steady state, the analysts said.RBC also noted that Yuviwel had more than 220 unique patient enrollments by July 31, up from over 170 at the end of Q2, while its prescriber base expanded to more than 100, with about 80% of centers of excellence already prescribing the drug. Ascendis expects an EMA decision in Q4, the note said.Ascendis maintained its 2026 operating cash flow guidance of more than 500 million euros, while RBC said the company remains confident about the ongoing ITC dispute, with a preliminary opinion expected Aug. 21 and a full commission decision expected in December, the report added.RBC maintains its outperform rating on the stock and raised its price target to $290 from $280.Price: $245.22, Change: $-1.01, Percent Change: -0.41%
Ascendis Pharma (ASND) share weakness following its Q2 update was not warranted, as all three commercial products topped consensus revenue estimates and management reiterated long-term revenue targets, Wedbush Securities said in a note Thursday.The firm sees intact, if not stronger, long-term potential in the company, according to the note.The brokerage said near-term intellectual property uncertainty around newly launched Yuviwel for achondroplasia likely drove the share decline, but pointed to a strong US launch, with more than 220 unique patient enrollments through July 31, up from over 170 a month earlier.Wedbush also cited continued growth for Yorvipath, the company's hypoparathyroidism treatment, supported by steady patient demand and a 95% retention rate.Wedbush maintained its outperform rating on the stock with the price target of $327.Price: $246.87, Change: $-8.59, Percent Change: -3.36%
European equities traded in the US as American depositary receipts were higher late Thursday morning, rising 0.45% to 1,969.72 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and biotech firm Evaxion (EVAX), which rose 4.9% and 2.9% respectively. They were followed by telecommunications company Nokia (NOK) and healthcare tech company Royal Philips (PHG), which increased 2.8% and 1.9% respectively.The decliners from continental Europe were led by Ascendis Pharma (ASND) and petroleum refiner Equinor (EQNR), which fell 3.8% and 2.8% respectively. They were followed by oil and gas company Eni (E) and pharmaceutical company Novo Nordisk (NVO), which were down 1.8% and 0.7% respectively.The gainers from the UK were led by Autolus Therapeutics (AUTL) and Silence Therapeutics (SLN), which rose 4.7% and 3.6% respectively. They were followed by software firm Endava (DAVA) and British American Tobacco (BTI), which were up 3.3% and 2.9% respectively.The decliners from the UK and Ireland were led by Trinity Biotech (TRIB) and Mereo BioPharma Group (MREO), which lost 3% and 2.5% respectively. They were followed by mining firm BHP (BHP) and oil and gas company BP (BP), which fell 1.8% and 1.5% respectively.
Healthcare stocks were advancing pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) 0.6% higher.MeiraGTx (MGTX) shares were up more than 7% after the company reported that it swung to a Q2 net income as revenue surged during the period.Cullinan Therapeutics (CGEM), Taiho Oncology and Taiho Pharmaceutical said a phase 3 clinical trial evaluating the combination of their jointly developed drug zipalertinib and chemotherapy as a first-line treatment for adults with previously untreated, locally advanced or metastatic non-small cell lung cancer met its primary endpoint of progression-free survival. Shares of Cullinan Therapeutics were up more than 7% premarket.Ascendis Pharma (ASND) stock was up more than 1% after the company posted higher Q2 non-IFRS earnings and revenue.
European equities traded in the US as American depositary receipts were heading higher late Thursday morning, rising 0.85% to 1,947.79 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by accommodations booking site trivago (TRVG) and pharmaceutical company Ascendis Pharma (ASND), which advanced 4.8% and 2.2% respectively. They were followed by lender Banco Bilbao Vizcaya Argentaria (BBVA) and internet ad firm Criteo (CRTO), which were up 1.7% and 0.9% respectively.The decliners from continental Europe were led by biotech firm BioNTech (BNTX) and internet browser company Opera (OPRA), which dropped 2.3% and 2.1% respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and biotech company Evaxion (EVAX), which lost 1.8% and 1.3% respectively.The gainers from the UK were led by communications company WPP (WPP) and biotech firm Trinity Biotech (TRIB), which surged 26% and 11% respectively. They were followed by biotech company Autolus Therapeutics (AUTL) and alcoholic beverage company Diageo (DEO), which rose 5.3% and 4.4% respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and medical device maker Smith & Nephew (SNN), which fell 4.4% and 1.9% respectively. They were followed by educational publisher Pearson (PSO) and biopharmaceutical company Mereo BioPharma Group (MREO), which were down 1.6% and 1.2% respectively.
European equities traded in the US as American depositary receipts rose late Tuesday morning with the S&P Europe Select ADR Index gaining 0.6% to 1,941.81.From continental Europe, the gainers were led by semiconductor company Sequans Communications (SQNS) and medical device maker EDAP TMS (FOCL), which climbed 11% and 5.3%, respectively. They were followed by telecommunications company Nokia (NOK) and internet ad firm Criteo (CRTO), which advanced 5.2% and 3.2%, respectively.The decliners from continental Europe were led by petroleum refiner Equinor (EQNR) and oil and gas company Eni (E), which fell 2.1% and 1.8%, respectively. They were followed by accommodations platform trivago (TRVG) and pharmaceutical company Ascendis Pharma (ASND), which were down 0.9% each.The gainers from the UK were led by mining company BHP Group (BHP) and pharmaceutical company Silence Therapeutics (SLN), which rose 3.8% and 3%, respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and lender Barclays (BCS), which were up 2.5% and 1.3%, respectively.The decliners from the UK and Ireland were led by medical device maker Smith & Nephew (SNN) and oil and gas company BP (BP), which dropped 5.8% and 4%, respectively. They were followed by educational publisher Pearson (PSO) and oil and gas company Shell (SHEL), which lost 1.6% and 1.4%, respectively.
European equities traded in the US as American depositary receipts were tracking lower late Wednesday morning, falling 1.11% to 1,892.74 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by petroleum refiner Equinor (EQNR) and oil and gas company Eni (E), which rose 2.4% each. They were followed by accommodations booking site trivago (TRVG) and pharmaceutical company Ascendis Pharma (ASND), which gained 1.7% and 0.7%, respectively.The decliners from continental Europe were led by lender Banco Santander (SAN) and software company SAP (SAP), which fell 5.1% and 3.7%, respectively. They were followed by internet advertising company Criteo (CRTO) and biopharmaceutical company Cellectis (CLLS), which declined 3.5% and 1.1%, respectively.The gainers from the UK were led by oil and gas company BP (BP) and biotech company Autolus Therapeutics (AUTL), which advanced 1.7% and 1.6%, respectively. They were followed by telecommunications company Vodafone Group (VOD) and educational publisher Pearson (PSO), which each gained 0.5%.The decliners from the UK and Ireland were led by biotech company Trinity Biotech (TRIB) and pharmaceutical company Silence Therapeutics (SLN), which dropped 5.9% and 5.6%, respectively. They were followed by communications company WPP (WPP) and biopharmaceutical company Akari Therapeutics (AKTX), which fell 4.7% and 3.8%, respectively.
Ascendis Pharma's (ASND) Yorvipath hypoparathyroidism therapy maintains a superior clinical profile compared with competing programs, Wedbush analysts said in a Monday note.The company's 3.5-year data from the phase-3 PaTHway study and the 5-year data from the phase-2 PaTH Forward study of Yorvipath in hypoparathyroidism provide strong evidence for sustained clinical benefit from long-term treatment, analysts said.Wedbush said that both studies showed high retention rates, durable efficacy, and continued improvement in renal function with longer treatment.Quality of life improvement, which is now required by the FDA for approvals, is the strongest evidence for Yorvipath's efficacy, a key opinion leader said, according to analysts.Wedbush has an outperform rating and a $273 price target on the stock.Price: $223.74, Change: $+5.68, Percent Change: +2.60%
European equities traded in the US as American depositary receipts were trending higher late Friday morning, rising 0.53% to 1,917.29 on the S&P Europe Select ADR Index, which is up more than 2% for the week so far.From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and telecommunications company Nokia (NOK), which advanced 8.2% and 5.8% respectively. They were followed by biopharmaceutical company DBV Technologies (DBVT) and pharmaceutical company Ascendis Pharma (ASND), which increased 4.8% and 3.2% respectively.The decliners from continental Europe were led by accommodations booking company trivago (TRVG) and medical device maker EDAP TMS (FOCL), which dropped 3.2% and 1.5% respectively. They were followed by software firm SAP (SAP) and semiconductor company Sequans Communications (SQNS), which lost 1.3% and 0.6% respectively.The gainers from the UK were led by biopharmaceutical company Mereo BioPharma Group (MREO) and software firm Endava (DAVA), which rose 3.7% and 3.4% respectively. They were followed by pharmaceutical company Silence Therapeutics (SLN) and biotech firm Autolus Therapeutics (AUTL), which were up 2.7% and 1.9% respectively.The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Akari Therapeutics (AKTX), which fell 3.7% and 3.4% respectively. They were followed by medical device maker Smith & Nephew (SNN) and pharmaceutical company AstraZeneca (AZN), which were off 0.9% and 0.6% respectively.
European equities traded in the US as American depositary receipts were rising late Friday morning, up 0.61% to 1,880.61 on the S&P Europe Select ADR Index, which is nearly flat for the week so far.From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and biotech firm BioNTech (BNTX), which rose 4.3% and 3% respectively. They were followed by software company SAP (SAP) and internet advertising firm Criteo (CRTO), which were up 2% and 0.4% respectively.The decliners from continental Europe were led by pharmaceutical company Ascendis Pharma (ASND) and telecommunications company Nokia (NOK), which fell 7.3% and 3% respectively. They were followed by accommodations booking site trivago (TRVG) and biopharmaceutical company Cellectis (CLLS), which were off 0.9% and 0.8% respectively.The gainers from the UK were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and communications company WPP (WPP), which advanced 2.4% and 1.1% respectively. They were followed by lenders Barclays (BCS) and HSBC (HSBC), which increased 1% and 0.9% respectively.The decliners from the UK and Ireland were led by biopharmaceutical companies Mereo BioPharma Group (MREO) and NuCana (NCNA), which dropped 6.6% and 4.4% respectively. They were followed by pharmaceutical company Silence Therapeutics (SLN) and tobacco company British American Tobacco (BTI), which lost 3.5% and 1.8% respectively.
European equities traded in the US as American depositary receipts were trending higher late Tuesday morning, rising 0.73% to 1,891.94 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by accommodations booking site trivago (TRVG) and telecommunications company Nokia (NOK), which rose 6.4% and 4.8% respectively. They were followed by lenders Banco Bilbao Vizcaya Argentaria (BBVA) and Banco Santander (SAN), which were up 4.4% and 3.8% respectively.The decliners from continental Europe were led by pharmaceutical company Ascendis Pharma (ASND) and petroleum refiner Equinor (EQNR), which fell 3% and 2% respectively. They were followed by internet advertising firm Criteo (CRTO) and pharmaceutical company Novo Nordisk (NVO), which were down 1.1% and 0.2% respectively.The gainers from the UK were led by biopharmaceutical company Mereo BioPharma Group (MREO) and pharmaceutical company Silence Therapeutics (SLN), which climbed 16% and 6.3% respectively. They were followed by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which advanced 4.5% and 3.1% respectively.The decliners from the UK and Ireland were led by oil and gas company BP (BP) and biopharmaceutical company NuCana (NCNA), which dropped 5% and 2.4% respectively. They were followed by biopharmaceutical company Amarin (AMRN) and communications company WPP (WPP), which lost 1.6% and 1.5% respectively.
European equities traded in the US as American depositary receipts were heading higher late Monday morning, rising 0.88% to 1,825.10 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and healthcare tech company Royal Philips (PHG), which rose 4.6% and 2.9% respectively. They were followed by internet advertising firm Criteo (CRTO) and biopharmaceutical company Grifols (GRFS), which were up 2.8% each.The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and biotech firm BioNTech (BNTX), which dropped 3.2% and 2% respectively. They were followed by telecommunications company Nokia (NOK) and pharmaceutical company Ascendis Pharma (ASND), which were down 1.9% and 0.9% respectively.The gainers from the UK were led by biotech companies Autolus Therapeutics (AUTL) and Trinity Biotech (TRIB), which climbed 16% and 6.2% respectively. They were followed by communications company WPP (WPP) and educational publisher Pearson (PSO), which advanced 4.8% and 4.7% respectively.The decliners from the UK and Ireland were led by biopharmaceutical companies NuCana (NCNA) and Biodexa Pharmaceuticals (BDRX), which fell 8.3% and 3% respectively. They were followed by biopharmaceutical companies Amarin (AMRN) and Mereo BioPharma Group (MREO), which were off 2.1% and 1% respectively.
European equities traded in the US as American depositary receipts were little changed late Wednesday morning, edging 0.08% higher to 1,829.64 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by telecommunications company Nokia (NOK) and biotech firm Evaxion (EVAX), which rose 4.1% and 3.9% respectively. They were followed by pharmaceutical company Ascendis Pharma (ASND) and accommodations booking site trivago (TRVG), which were up 0.5% and 0.3% respectively.The decliners from continental Europe were led by software firm SAP (SAP) and medical device maker EDAP TMS (EDAP), which dropped 4.8% and 4.7% respectively. They were followed by biopharmaceutical company DBV Technologies (DBVT) and furniture maker Natuzzi (NTZ), which lost 1.9% and 1.8% respectively.The gainers from the UK were led by biopharmaceutical company Akari Therapeutics (AKTX) and biotech firm Autolus Therapeutics (AUTL), which rose 11% and 4.7% respectively. They were followed by mining company BHP Group (BHP) and telecommunications operator Vodafone Group (VOD), which were up 2.7% and 2.2% respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Mereo BioPharma Group (MREO) and software firm Endava (DAVA), which fell 3.1% and 2.9% respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and educational publisher Pearson (PSO), which were down 2.1% and 1.4% respectively.
European equities traded in the US as American depositary receipts were tracking lower late Thursday morning, losing 0.87% to 1,830.89 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and accommodations booking company trivago (TRVG), which advanced 12% and 8%, respectively. They were followed by internet advertising firm Criteo (CRTO) and software company SAP (SAP), which increased 3.8% and 3.5%, respectively.The decliners from continental Europe were led by telecommunications company Nokia (NOK) and petroleum refiner Equinor (EQNR), which fell 4.4% and 4.3%, respectively. They were followed by semiconductor company Sequans Communications (SQNS) and pharmaceutical company Ascendis Pharma (ASND), which were down 2.7% and 2.3% respectively.The gainers from the UK were led by biopharmaceutical companies Akari Therapeutics (AKTX) and Biodexa Pharmaceuticals (BDRX), which rose 5.3% and 3.8% respectively. They were followed by communications company WPP (WPP) and hospitality company InterContinental Hotels Group (IHG), which were up 2.7% and 2.3% respectively.The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Bicycle Therapeutics (BCYC), which lost 4.9% and 3.2% respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and oil and gas company Shell (SHEL), which dropped 2.7% and 2.6% respectively.
European equities traded in the US as American depositary receipts were higher late Wednesday morning, edging up 0.12% to 1,808.88 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by oil and gas firm Eni (E) and semiconductor firm Sequans Communications (SQNS), which rose 1.8% and 1.5% respectively. They were followed by 3D printer company Materialise (MTLS) and internet advertising firm Criteo (CRTO), which were up 1.1% and 0.7% respectively.The decliners from continental Europe were led by telecommunications company Nokia (NOK) and Ascendis Pharma (ASND), which fell 4.1% and 4% respectively. They were followed by medical device maker EDAP TMS (EDAP) and biotech firm Evaxion (EVAX), which were down 1.8% and 0.2% respectively.The gainers from the UK were led by mining company BHP Group (BHP) and pharmaceutical company Silence Therapeutics (SLN), which advanced 3% and 2.9% respectively. They were followed by utilities company National Grid (NGG) and telecommunications operator Vodafone (VOD), which increased 2.8% and 1.6% respectively.The decliners from the UK and Ireland were led by Akari Therapeutics (AKTX) and Biodexa Pharmaceuticals (BDRX), which dropped 3.8% and 3.4% respectively. They were followed by alcoholic beverage company Diageo (DEO) and hospitality company InterContinental Hotels Group (IHG), which lost 1.8% and 1.4% respectively.
European equities traded in the US as American depositary receipts were falling sharply late Tuesday morning, dropping 1.15% to 1,812.72 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by petroleum refiner Equinor (EQNR) and internet browser company Opera (OPRA), which rose 2.7% and 1.7% respectively. They were followed by 3D printer company Materialise (MTLS) and medical device maker EDAP TMS (EDAP), which were up 1.2% each.The decliners from continental Europe were led by biopharmaceutical company argenx (ARGX) and pharmaceutical company Novo Nordisk (NVO), which fell 3% and 2.8% respectively. They were followed by biotech firm Evaxion (EVAX) and pharmaceutical company Ascendis Pharma (ASND), which were down 2.7% each.The gainers from the UK were led by biopharmaceutical company Akari Therapeutics (AKTX) and software firm Endava (DAVA), which advanced 6.4% and 2.7% respectively. They were followed by education company Pearson (PSO) and pharmaceutical company Silence Therapeutics (SLN), which increased 1.2% and 0.9% respectively.The decliners from the UK and Ireland were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and NuCana (NCNA), which dropped 8.7% and 3.2% respectively. They were followed by biopharmaceutical company Mereo BioPharma Group (MREO) and cruise line operator Carnival (CUK), which lost 2.3% and 2.2% respectively.
Showing 1-20 of 23
